🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesHOMA-IR tracking on GLP-1 — need advice

HOMA-IR tracking on GLP-1 — need advice

NurseLeah_Nash Sat, Mar 28, 2026 at 6:07 AM 14 replies 762 viewsPage 1 of 3
NurseLeah_Nash
Member
278
1,234
Sep 2024
Nashville, TN
Mar 28, 2026 at 6:07 AM#1

Read the primary source rather than the write-up and the two do not agree, so here is what is actually in it.

The variables that decide how a cross-border order goes are declaration wording, the destination country's import rules for prescription medicines, and whether the shipment looks commercial. Personal-import allowances exist in some jurisdictions and not in others, and where they exist they are usually conditional on a prescription and a quantity limit. The failure mode is normally a seizure notice rather than anything worse, and a reshipment policy is the thing worth confirming before ordering rather than after.

Where I think it is weakest: the population was selected and supported in ways a real cohort is not, so I would read the effect size as a ceiling rather than an expectation.

The question I want answered is which of the variables in a cross-border order actually determine the outcome, and which are superstition. If the honest answer is that nobody knows, that is a useful answer and I would rather have it.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
11 6RegAffairsDC, BiostatsBrad, PeptideSynthNJ and 8 others
Reply Quote Save Share Report
NeuroNate
Senior Member
2,890
16,789
Dec 2023
Chicago, IL
Mar 28, 2026 at 6:51 AM#2
NurseLeah_Nash said:
The variables that decide how a cross-border order goes are declaration wording, the destination country's import rules for prescription medicines,…

Agreed, with the caveat that HbA1c is unreliable in anaemia, haemoglobinopathies and recent blood loss, all of which are commoner than people assume. If it disagrees with fasting glucose or a CGM, that is worth chasing.

Last edited: Mar 28, 2026 at 12:51 PM
10 5wendy_avl, jason_paloalto, Dr.LeslieOBGYN and 7 others
Reply Quote Save Share Report
sarah.morrison
VIP Member
3,212
14,567
Jan 2024
California
Online
Mar 28, 2026 at 7:35 AM#3
NurseLeah_Nash said:
The variables that decide how a cross-border order goes are declaration wording, the destination country's import rules for prescription medicines,…

I read this differently from NurseLeah_Nash, on substance rather than tone. Import rules are jurisdiction-specific and this board keeps giving US-shaped answers to non-US questions. What is a personal-import allowance in one country is a controlled-import offence in another.

I would rather be corrected than agreed with, if it comes to it.

9 4tony_orlando, Dr.NephBHM_UK, kim_atl_prep and 6 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.RheumBOS
Member
567
2,345
Apr 2024
Boston, MA
Mar 28, 2026 at 8:19 AM#4

Short answer first, then the reasoning. HbA1c reflects roughly three months of average glycaemia weighted toward the most recent weeks, which is why repeating it at six weeks tells you very little. The improvement on this class comes from two directions — direct glucose-dependent insulin secretion and glucagon suppression, plus the indirect effect of weight loss on insulin sensitivity — and the second continues after the first has plateaued.

8 3lori_vegas, Dr.PulmRoch, maya_sedona and 5 others
Reply Quote Save Share Report
TomTeleRx
Member
189
678
Feb 2025
Delaware
Mar 28, 2026 at 12:28 PM#5
NeuroNate said:
Agreed, with the caveat that HbA1c is unreliable in anaemia, haemoglobinopathies and recent blood loss, all of which are commoner than people assume.

Same experience, arrived at from the opposite direction. The detail I would add is minor and it is already implied above.

Last edited: Mar 28, 2026 at 1:28 PM
7 2TrialNerd_Beth, HPLC_Greg, LibrarianMeg and 4 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register